USANA HEALTH SCIENCES INC

USANA Health Sciences faces steep losses, a negative P/E and volatile stock; investors must weigh its global supplement niche against troubling finances.

USANA Health Sciences Inc. has demonstrated financial resilience and strategic foresight despite a decade of market volatility, with recent earnings exceeding expectations and revenue figures reaching $236 million.

USANA Health Sciences Inc. has seen a 63.76% decline in its stock value over the past five years, from $82.86 in 2020 to $30.03 in 2025.